Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

ESMO 2017: Adjuvant Opdivo (Nivolumab) superior to Yervoy (Ipilimumab) in surgically resected stage III/IV melanoma

Go Top